Adastra Holdings Ltd. is a Canada-based company, which is engaged in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. The Company serves medical markets and engages in forward-looking therapeutic applications. With cannabis concentrate products sold through retailers at more than 2,000 locations across Canada, its Phyto Extractions and Endgame Extracts brands are established with a distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. The Company partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - Canadian Securities Exchange 12:28:52 2026-04-15 EDT			5-day change	1st Jan Change
0.2000 ^CAD	-.--%		-.--%	-14.89%

05-04	Adastra Holdings Ltd. Announces Director Changes, Effective April 30, 2026	CI
04-29	Adastra Holdings Ltd. Announces Resignation of Paul Morgan as Director, Effective April 28, 2026	CI

Market Cap	1.32M 940K 840K 776K 703K 89.27M 1.34M 9.34M 3.7M 46.77M 3.53M 3.45M 147M	P/E 2023	-3.47x	P/E 2024	-0.1x
Enterprise Value	3.64M 2.6M 2.32M 2.15M 1.95M 247M 3.7M 25.83M 10.23M 129M 9.77M 9.56M 408M	EV / Sales 2023	655,990x	EV / Sales 2024	144,247x
Free-Float	98.73%	Yield 2023 *	-	Yield 2024	-

05-04	Adastra Holdings Ltd. Announces Director Changes, Effective April 30, 2026	CI
04-29	Adastra Holdings Ltd. Announces Resignation of Paul Morgan as Director, Effective April 28, 2026	CI
03-02	Adastra Holdings Ltd. Announces Resignation of Mark Qvist as Director, Effective February 28, 2026	CI
12-01	Adastra Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-14	An undisclosed buyer completed the acquisition of 1178562 B.C. Ltd. from Adastra Holdings Ltd..	CI
25-10-14	An undisclosed buyer completed the acquisition of Adastra Brands Inc. from Adastra Holdings Ltd..	CI
25-10-07	An undisclosed buyer agreed to acquire Adastra Brands Inc. from Adastra Holdings Ltd. for CAD 5000.	CI
25-10-07	An undisclosed buyer agreed to acquire Adastra Labs Holdings Ltd. from Adastra Holdings Ltd. for CAD 0.50 million.	CI
25-08-29	Adastra Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-30	Adastra Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-28	Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-27	Adastra Holdings Ltd. Auditor Raises 'Going Concern' Doubt	CI
25-03-03	Adastra Holdings Ltd. Appoints Mark Qvist as Member of Its Board of Directors	CI

05-12	Canadian Investment Regulatory Organization Trading Halt - XTRX	AQ
05-04	Adastra Holdings Ltd. Appoints New Director	NE
04-29	Adastra Holdings Announces Resignation of Director	NE
03-02	Adastra Holdings Announces Agreement to Sell Assets and Resignation of Director	NE
25-10-15	Adastra Holdings Announces Completion of Sale of Subsidiaries	NE

Adastra Holdings Ltd. Stock

Stocks

XTRX

CA00654D2095

Pharmaceuticals

Valuation: Adastra Holdings Ltd.

Chart: Adastra Holdings Ltd.

Latest news: Adastra Holdings Ltd.

Press Releases: Adastra Holdings Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Adastra Holdings Ltd.

Alternative Medicine

Financials

Company Profile

Current year	0.2	0.27
1 year	0.2	0.27
3 years	0.15	3.05
5 years	0.15	20
10 years	0.15	29.7

Director	Title	Age	Since
Jonathan Edwards BRD	Director/Board Member	-	2024-04-01
Calum Maschi BRD	Director/Board Member	-	2026-04-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADASTRA HOLDINGS LTD.	-.--%	-.--%	-4.76%	-91.30%	800K
ELI LILLY AND COMPANY	-2.54%	+1.31%	+55.10%	+120.84%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+37.07%	+74.26%	636B
ABBVIE INC.	+0.16%	+0.08%	+25.14%	+97.36%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.63%	+40.56%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	266B
AMGEN INC.	-1.79%	+1.57%	+49.97%	+60.87%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.24%	+101.19%	193B
Average	-0.60%	+1.95%	+32.74%	+54.68%	400.43B
Weighted average by Cap.	-0.26%	+2.66%	+40.99%	+82.13%

	2023	2024
Net sales	22.22 15.89 14.19 13.11 11.88 1.51K 22.59 157.73 62.45 790.24 59.63 58.36 2.49K	24.84 17.76 15.86 14.65 13.28 1.69K 25.25 176.33 69.81 883.44 66.66 65.24 2.79K
Net income	-3.54M -2.53M -2.26M -2.09M -1.89M -241M -3.6M -25.16M -9.96M -126M -9.51M -9.31M -397M	-13.24M -9.46M -8.45M -7.81M -7.07M -898M -13.45M -93.94M -37.19M -471M -35.51M -34.76M -1.48B
Net Debt	2.26M 1.62M 1.45M 1.34M 1.21M 154M 2.3M 16.07M 6.36M 80.52M 6.08M 5.95M 254M	2.32M 1.66M 1.48M 1.37M 1.24M 158M 2.36M 16.5M 6.53M 82.65M 6.24M 6.1M 261M